Replies to post #617 on reaper board

[12yearplan]

Ok Reap,

    Here's my attempt at a recco for you (mark this post ;) :-

    Speculative play/disrupter in the CBD sector CRDL

    One million units going on the shelves as we speak (if all sold give them $10M in the black)
    and other carrot is FDA phase one heart muscle medicine Univ. of Alta development

    Hammer, bounce off 52 week low (not quite 52) Friday
    Rest of chart is bearish (52 week low ffs!)

    All comments/better dd welcome ;)

https://cannabisdaily.today/cardiol-therapeutics-at-the-intersection-of-pharmaceutical-cbd-and-biotech-plus-exclusive-ceo-interview/

https://www.cardiolrx.com/product-pipeline/heart-failure-products/

https://www.cardiolrx.com/cardiol-therapeutics-granted-exclusive-global-license-to-nanotechnology-for-pharmaceutical-cannabidiol/

Cardiol Therapeutics is a company with significant near- and long-term catalysts for growth and we believe that this opportunity is flying under the radar. The company is led by a management team that has been laser focused on achieving important milestones and we are impressed with how the story has evolved so far this year.

Heading into 2020, we believe that Cardiol represents one of the most attractive long-term opportunities to have on your radar. When looking at the most significant potential catalysts for Cardiol, we are looking for the company to announce distribution agreements for the sale of CardiolRx™ in Canada. The entry into additional international markets in Europe or in Latin America would also represent a major advancement in the story. And finally, the advancement of clinical programs designed to demonstrate the impact of CardiolRx™ and CTX formulations on inflammatory heart disease will be a significant catalyst for the company.

https://www.technical420.com/cannabis-article/cardiol-therapeutics-has-a-major-near-term-catalyst-right-around-the-corner-with-the-proposed-launch-of-cardiolrx/#

 Even though its increasing cash burn makes us a little nervous, we are compelled to mention that we thought Cardiol Therapeutics's cash burn relative to its market cap was relatively promising. One real positive is that at least one analyst is forecasting that the company will reach breakeven. We don't think its cash burn is particularly problematic, but after considering the range of factors in this article, we do think shareholders should be monitoring how it changes over time. When you don't have traditional metrics like earnings per share and free cash flow to value a company, many are extra motivated to consider qualitative factors such as whether insiders are buying or selling shares. Please Note: Cardiol Therapeutics insiders have been trading shares, according to our data.
 https://finance.yahoo.com/news/cardiol-therapeutics-tse-crdl-spend-113955218.html?.tsrc=rss

https://media.farandwide.com/e1/3b/e13b54d28f14453eaee51934f4c10963.jpeg